Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:7185708.
doi: 10.1155/2016/7185708. Epub 2016 Jul 31.

Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis

Chunxiao Wu  1 , Shengxu Wang  1 , Peifeng Xian  1 , Lu Yang  2 , Ying Chen  2 , Xianjie Mo  3
Affiliations
Review

Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis

Chunxiao Wu et al. Biomed Res Int. 2016.

Abstract

Background. Antitumor necrosis factor (anti-TNF) drugs have been applied for rheumatoid arthritis (RA) treatment; however, patients having anti-drug antibodies (ADAbs) do not benefit from these drugs. The meta-analysis aims to comprehensively assess the relationship between ADAb positive (ADAb+) and anti-TNF response in RA patients. Methods. Observational studies comparing different clinical response between ADAb+ and ADAb negative groups were included. Odds ratio (OR) with its corresponding 95% confidence interval (CI) was used as effect size. Subgroup analyses stratified by TNF inhibitor types and assay methods for ADAb detection were performed. Results. Totally, 10 eligible studies containing 1806 subjects were included. ADAb+ was significantly associated with reduced anti-TNF response to RA at all the time points after follow-up (P < 0.001). Subgroup analysis also supported this significant association (P < 0.05), except for enzyme-linked immunosorbent assay (ELISA) group at 3 months, infliximab (INF) and enzyme-linked immunosorbent assay (ELISA) groups at 6 months, and Immunological Multi-Parameter Chip Technology (IMPACT) group at 12 months. Conclusion. ADAb+ was significantly associated with reduced clinical response in RA patients, and other alternatives should be considered in RA patients presenting ADAb+.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Procedures of study selection.
Figure 2
Figure 2
Effect of ADAb+ on anti-TNF response in rheumatoid arthritis patients, compared with ADAb− group at different time points after follow-up. (a) At 3 months; (b) at 6 months; (c) at 12 months; (d) at >24 months.
See this image and copyright information in PMC

References

    1. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Reviews Immunology. 2002;2(5):364–371. doi: 10.1038/nri802. - DOI - PubMed
    1. Fleischmann R., Kremer J., Cush J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New England Journal of Medicine. 2012;367(6):495–507. doi: 10.1056/NEJMoa1109071. - DOI - PubMed
    1. Aggarwal B. B. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology. 2003;3(9):745–756. doi: 10.1038/nril184. - DOI - PubMed
    1. Chaabo K., Kirkham B. Rheumatoid arthritis—anti-TNF. International Immunopharmacology. 2015;27(2):180–184. doi: 10.1016/j.intimp.2015.04.051. - DOI - PubMed
    1. Galloway J. B., Hyrich K. L., Mercer L. K., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50(1):124–131. doi: 10.1093/rheumatology/keq242. - DOI - PMC - PubMed